$TEM

Rogers James William sold $634K of TEM

Rogers James William (Chief Financial Officer) sold 11,529 shares of Tempus AI, Inc. (TEM) at $55.00 ($0.63M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rogers James William
Published Jun 30, 2026, 12:40 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CFO for ~$634k, executed under a pre-arranged 10b5-1 plan; this is generally treated as routine unless paired with other negative fundamentals.

02

Market read

Traders may monitor for insider selling trends, but this specific disclosure is unlikely to drive a major repricing on its own.

03

What to watch

The filing does not disclose reasons for the sale beyond the existence of a 10b5-1 plan; without additional context (e.g., other insiders buying, earnings timing), the signal is weak.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed late June 29; sale dated June 25.

Background

The article summarizes an SEC Form 4 insider transaction for Tempus AI, Inc. (TEM) involving the CFO.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI CFO Rogers James William sold 11,529 shares in an open-market transaction for about $634,095 under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing the likelihood of new, time-sensitive negative information.

Market effects

Minimal—this is company-specific insider transaction data with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still reflect management’s view of valuation or liquidity needs; traders may still fade rallies if selling cadence continues.

Key entities

  • Tempus AI, Inc.

    Issuer of the Form 4 insider transaction; ticker TEM.

  • Rogers James William

    Chief Financial Officer who sold 11,529 shares.

  • 10b5-1 plan

    Pre-arranged trading plan that reduces the informational content of the sale timing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.